Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy VBI Vaccines stock | $3.08

Own VBI Vaccines stock in just a few minutes.

Posted

Fact checked

VBI Vaccines Inc is a biotechnology business based in the US. VBI Vaccines shares (VBIV) are listed on the NASDAQ and all prices are listed in US Dollars. VBI Vaccines employs 123 staff and has a trailing 12-month revenue of around USD$1.8 million.

How to buy shares in VBI Vaccines

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for VBI Vaccines Find the stock by name or ticker symbol: VBIV. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until VBI Vaccines reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$3.08, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of VBI Vaccines, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of VBI Vaccines. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

VBI Vaccines share price

Use our graph to track the performance of VBIV stocks over time.

VBI Vaccines shares at a glance

Information last updated 2020-09-25.
Latest market closeUSD$3.08
52-week rangeUSD$0.4655 - USD$6.93
50-day moving average USD$3.6011
200-day moving average USD$2.6152
Wall St. target priceUSD$8.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.758

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Available asset types Stock trade fee Option trade fee Annual fee
Vanguard
Stocks,Mutual funds,ETFs,Forex
$0
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
Stocks,Options,ETFs,Cryptocurrency
$0
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
TD Ameritrade
Stocks,Bonds,Options,Mutual funds,ETFs,Forex,Futures
$0
or $25 If it is broker-assisted
$0 + $0.65/contract,
or $25 Broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Interactive Brokers
Stocks,Bonds,Options,Mutual funds,Index funds,ETFs,Forex,Futures,Cash
$0
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
Stocks,Options,ETFs,Futures
$0
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy VBI Vaccines stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

VBI Vaccines price performance over time

Historical closes compared with the close of $3.08 from 2020-09-25

1 week (2020-09-24) 5.84%
1 month (2020-09-01) -19.16%
3 months (2020-07-01) 4.76%
6 months (2020-04-01) 253.58%
1 year (2019-10-01) 543.41%
2 years (2018-10-01) 27.80%
3 years (2017-09-29) -20.00%
5 years (2015-10-01) 1,711.76%

VBI Vaccines financials

Revenue TTM USD$1.8 million
Gross profit TTM USD$-5,683,000
Return on assets TTM -17.03%
Return on equity TTM -44.27%
Profit margin 0%
Book value $0.549
Market capitalisation USD$672.8 million

TTM: trailing 12 months

Shorting VBI Vaccines shares

There are currently 15.9 million VBI Vaccines shares held short by investors – that's known as VBI Vaccines's "short interest". This figure is 25.5% up from 12.7 million last month.

There are a few different ways that this level of interest in shorting VBI Vaccines shares can be evaluated.

VBI Vaccines's "short interest ratio" (SIR)

VBI Vaccines's "short interest ratio" (SIR) is the quantity of VBI Vaccines shares currently shorted divided by the average quantity of VBI Vaccines shares traded daily (recently around 17.7 million). VBI Vaccines's SIR currently stands at 0.9. In other words for every 100,000 VBI Vaccines shares traded daily on the market, roughly 900 shares are currently held short.

However VBI Vaccines's short interest can also be evaluated against the total number of VBI Vaccines shares, or, against the total number of tradable VBI Vaccines shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VBI Vaccines's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 VBI Vaccines shares in existence, roughly 70 shares are currently held short) or 0.0934% of the tradable shares (for every 100,000 tradable VBI Vaccines shares, roughly 93 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against VBI Vaccines.

Find out more about how you can short VBI Vaccines stock.

VBI Vaccines share dividends

We're not expecting VBI Vaccines to pay a dividend over the next 12 months.

Have VBI Vaccines's shares ever split?

VBI Vaccines's shares were split on a 1:40 basis on 2 May 2016. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VBI Vaccines shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for VBI Vaccines shares which in turn could have impacted VBI Vaccines's share price.

VBI Vaccines share price volatility

Over the last 12 months, VBI Vaccines's shares have ranged in value from as little as $0.4655 up to $6.93. A popular way to gauge a stock's volatility is its "beta".

VBIV.US volatility(beta: 1.61)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VBI Vaccines's is 1.607. This would suggest that VBI Vaccines's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

VBI Vaccines overview

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site